Exciting times for patients with eosinophilic esophagitis (EoE): Dupilumab now approved in Canada for age 12 and up #CSACI12

Great keynote speaker Senator F. Gigi Osler on ways to advocate and improve health care for all backgrounds. Let’s create more spaces at the table, and make the table bigger! #bethechange #CSCAI23

Update on #allergicrhinitis Canadian Guidelines with Dr. Ellis #CSACI23

Allergic Rhinitis (AR) Guidelines update research Q1: Serum IgE is acceptable alternative to skin testing for diagnosis of AR and guiding immunotherapy for certain cases #CSACI23 Dr. Ellis

Allergic Rhinitis Guidelines update Q2: Either 2nd generation antihistamine or intranasal steroid may be 1st line; consider INS for patients with moderate to severe symptoms, and what the patient is going to be more compliant with may be better choice Dr. Ellis #CSACI23

Allergic Rhinitis Guidelines update Q3: Combination of intranasal antihistamine plus intranasal steroid (INS) is superior to INS plus oral antihistamine; they may be equivalent after prolonged use Dr. Ellis #CSACI23

Allergic Rhinitis Guidelines update Q4: Leukotriene receptor antagonist (LRTA) may improve night time symptoms, but may have neuropsychological symptoms esp <6y; LRTA have inferior or at best equivalent improvement vs oral anti-histamines Dr. Ellis #CSACI23

Allergic Rhinitis Guidelines update Q5: SLIT (sublingual) vs SCIT (Subcutaneous) immunotherapy are both effective - no long term head to head studies. Consider cost, risks, administration & patient preference; Important to pick one that patient will be adherent to Dr. Ellis

Allergic Rhinitis Guidelines update Q6: should all patients be offered SCIT or SLIT? Both reduce/ eliminate need for meds and may reduce risk of development of asthma. Both should be offered to patients not well controlled by meds or have a preference for treatment Dr. Ellis

Last day of #CSACI23 with Dr. Douglas Mack : Review of biologics in pediatrics for asthma, eczema, CSU and eosinophilic esphagitis. Great discussion on indications and barriers to prescribing such as cost and side effects.

When prescribing biologics in children, shared decision making with parents and families is important: discuss latest medical evidence, all their options, the risks, and use language they understand (LEARN, LISTEN, and SUPPORT) #CSACI23 Dr. Douglas Mack

Dr William Anderson #CSACI23 Biologics in severe asthma in pediatrics: Even one course of oral corticosteroids (OCS) increases a child's risk for sepsis, pneumonia and GI bleeding. Biologics help reduce their risk of exacerbation requiring OCS #asthma

Dr Anderson #CSACI23 There are gaps in evidence for use of biologics in children with severe asthma: Accessibility issues, biomarkers, limited safety data, comparison between biologics, and long term effects

Last session of #CSACI23 Pro con debate with Dr Harold Kim & Dr. Ellis on sublingual vs subcutaneous immunotherapy. Many advantages and disadvantages of both! (SLIT- safer, home dosing, no injection vs SCIT- well established, better adherence, possibly more disease modifying)

Thank you CSACI for another great Annual Scientific Meeting!! Hopefully see all my allergy and immunology colleagues in Banff 2024!!!

It's here. Introducing the schedule for our inaugural season! 🎉 📰 bit.ly/3uAJgaB

Ella Shelton (Ella Shelton) scores the first goal in PWHL HISTORY! 🎉

Go Moose Go! #gomoosego Halifax Mooseheads

Thank you hfxgov for plowing the bike lanes! Love that I can bike to work in February